Actively Recruiting
Methods of T Cell Depletion Trial (MoTD)
Led by University of Birmingham · Updated on 2026-05-05
400
Participants Needed
17
Research Sites
339 weeks
Total Duration
On this page
Sponsors
U
University of Birmingham
Lead Sponsor
T
The Jon Moulton Charity Trust
Collaborating Sponsor
AI-Summary
What this Trial Is About
A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
CONDITIONS
Official Title
Methods of T Cell Depletion Trial (MoTD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Availability of a suitably matched unrelated donor (9/10 or 10/10)
- Planned to receive one of the following reduced intensity conditioning protocols: Fludarabine-Melphalan, BEAM or LEAM, Fludarabine-Busulphan, or Fludarabine-Treosulfan
- Planned use of peripheral blood stem cells for transplantation
- Planned allogeneic stem cell transplant for specified haematological malignancies including AML, ALL, CMML (<10% blasts), MDS (<10% blasts), NHL, HL, MM, CLL, CML in 1st or 2nd chronic phase, or Myelofibrosis
- Age between 16 and 70 years
- Females and males of reproductive potential must agree to use appropriate, highly effective contraception from starting therapy until 12 months after transplant
You will not qualify if you...
- Use of any graft manipulation method not defined by the protocol (except storage of future donor lymphocyte infusion)
- Use of alemtuzumab or any T-cell depletion method outside the study protocol
- Known allergy to study drugs or history of rabbit hypersensitivity
- Pregnant or lactating women
- Adults of reproductive potential unwilling to use effective contraception during the study period
- Life expectancy less than 8 weeks
- Active hepatitis B or C infection
- Organ dysfunction including left ventricular ejection fraction below 45%, glomerular filtration rate below 50ml/min, bilirubin over 50 µmol/l, or liver enzymes (AST/ALT) more than 3 times the upper limit of normal
- Participation in COSI or ALL-RIC trials
- Contraindications to study drugs as per their safety information
- Other significant systemic dysfunction or disorders that could jeopardise patient safety during the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
University Hospital of Wales
Cardiff, Wales, United Kingdom, CF14 4XW
Actively Recruiting
2
Queen Elizabeth Hospital
Birmingham, United Kingdom, B15 2GW
Actively Recruiting
3
Bristol Haematology and Oncology Centre
Bristol, United Kingdom, BS2 8ED
Actively Recruiting
4
Addenbrookes Hospital
Cambridge, United Kingdom, CB2 0QQ
Actively Recruiting
5
Queen Elizabeth Hospital Glasgow
Glasgow, United Kingdom, G51 4TF
Actively Recruiting
6
St Jame's University Hospital
Leeds, United Kingdom, LS9 7TF
Actively Recruiting
7
University College London Hospital
London, United Kingdom, NW1 2BU
Actively Recruiting
8
King's College Hospital
London, United Kingdom, SE5 9RS
Actively Recruiting
9
Hammersmith Hospital
London, United Kingdom, W12 0HS
Actively Recruiting
10
Manchester Royal Infirmary
Manchester, United Kingdom, M13 9WL
Actively Recruiting
11
The Christie
Manchester, United Kingdom, M20 3QH
Actively Recruiting
12
Freeman Hospital
Newcastle upon Tyne, United Kingdom, NE7 7DN
Actively Recruiting
13
Nottingham City Hospital
Nottingham, United Kingdom, NG5 1PB
Actively Recruiting
14
Churchill Hospital
Oxford, United Kingdom, OX3 7LE
Actively Recruiting
15
Derriford Hospital
Plymouth, United Kingdom, PL6 8DH
Actively Recruiting
16
Royal Hallamshire Hospital
Sheffield, United Kingdom, S102JF
Actively Recruiting
17
The Royal Marsden Hospital
Sutton, United Kingdom, SM2 5PT
Actively Recruiting
Research Team
M
MoTD Trial
CONTACT
A
Andrea Dr Hodgkinson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here